IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2649
Positioning
Market Dominance
Manufacturing
Medical Equipment
$423M
Xingjuan (Jane) Chao
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We were incorporated under the laws of the State of Delaware on August 29, 2014, under the name “Brain Stethoscope, Inc.” and changed our name to CeriBell, Inc. on August 11, 2015. Our principal executive offices are located at 360 N. Pastoria Avenue, Sunnyvale, California.
Headcount
—
HQ Base
SUNNYVALE, California
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CBLL Ceribell, Inc. | 46 | 51 | 39 | 58 | - | - | -30.7% | -25.2% | 87.9% | -65.6% | -61.7% | 31.4% | 0.0% | 22.0x | $423M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Ceribell, Inc. (CBLL) receives a "Reduce" rating with a composite score of 45.9/100. It ranks #2649 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CBLL.
View All RatingsROE proxy -30.7% (sector -1.9%)
GM 88% vs sector 44%, OM -66% vs sector 3%
Capital turnover N/A, R&D intensity 21.9%
Rev growth 31%, 2yr history
Interest coverage -30.5x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Ceribell, Inc. (CBLL) as a Reduce with a composite score of 45.9/100 at a current price of $19.87. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Ceribell, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 45.9/100 places it at rank #2649 in our full universe.
Narrow
High
Poor
Fair Value
Gross margins of 88% signal strong pricing power.
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
Ceribell, Inc. represents a reduce based on multi-factor quantitative performance.
Ceribell, Inc. receives a Reduce rating from our analysis, with a composite score of 45.9/100 and 2 out of 5 stars, ranking #2649 out of 7,333 stocks. CBLL's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 51/100, CBLL shows adequate but unremarkable business quality. The company reports a return on equity of -30.7% (sector avg: -1.9%), gross margins of 87.9% (sector avg: 44.1%), net margins of -61.7% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
With a value score of 39/100, CBLL appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 4.57x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Ceribell, Inc.'s investment score of 24/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 31.4% vs. a sector average of 6.7% and a return on assets of -25.2% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CBLL demonstrates moderate momentum with a score of 58/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 31.4% year-over-year, while a beta of 1.69 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
CBLL's stability score of 42/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.69 and a debt-to-equity ratio of 22.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Ceribell, Inc.'s short interest score of 39/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.69), elevated leverage (D/E: 22.00x), small-cap liquidity risk. At $423M (small-cap), CBLL carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Ceribell, Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2649 of 7,333 overall (64th percentile). Key comparisons include ROE of -30.7% trailing the -1.9% sector median and operating margins of -65.6% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CBLL currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (24) would have the largest impact on the composite score.
ROE 1514% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 99% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 2714% BELOW SECTOR MEDIAN
SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming investor conferences. Scott Blumberg, CFO, will present at the upcoming Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026, at 1:00 p.m. Pacific Standard Time / 4:00 p.m.
CeriBell (NASDAQ:CBLL) reported fourth-quarter and full-year 2025 results that management said reflected continued penetration of its core seizure market alongside a broadened product and regulatory foundation intended to expand the company’s addressable opportunity. The company also provided 2026 r
The consensus estimate for Q4 2025 revenue is $23.94 million, and the earnings are expected to come in at -$0.41 per share. The full year 2025's revenue is expected to be $88.18 million and the earnings are expected to be -$1.51 per share. More detailed estimate data can be found on the Forecast page.
Above 50MA
37.18%
Net New Highs
+51081